Article
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
The oncologist - 1 Feb 2019
Xiong Liwen, Li Rong, Sun Jiayuan, Lou Yuqing, Zhang Weiyan, Bai Hao, Wang Huiming, Shen Jie, Jing Bo, Shi Chunlei, Zhong Hua, Gu Aiqin, Jiang Liyan, Shi Jianxing, Fang Wentao, Zhao Heng, Zhang Jie, Wang Junyuan, Ye Junyi, Han Baohui
Abstract excerpt
LESSONS LEARNED: The findings of this prospective, single-arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA-N2 epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC).Erlotinib shows promise as a neoadjuvant therapy option in this patient population.Next-generation sequencing may be useful...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.